Lower negotiated prices on widely used medicines directly reduce out-of-pocket health costs for older households, easing cost-of-living pressure for that group.

On 15 August 2024 the Biden administration and the Centers for Medicare & Medicaid Services announced the first set of negotiated prices for ten high-spend Medicare Part D drugs, the inaugural use of the Inflation Reduction Act's drug-price-negotiation authority. CMS said the prices, effective in 2026, would have saved Medicare about $6 billion had they applied in 2023 and were estimated to cut beneficiaries' out-of-pocket costs by roughly $1.5 billion. The program marks a structural change to US prescription-drug pricing for seniors.
On 15 August 2024 the Biden administration and the Centers for Medicare & Medicaid Services announced the first set of negotiated prices for ten high-spend Medicare Part D drugs, the inaugural use of the Inflation Reduction Act's drug-price-negotiation authority. CMS said the prices, effective in 2026, would have saved Medicare about $6 billion had they applied in 2023 and were estimated to cut beneficiaries' out-of-pocket costs by roughly $1.5 billion. The program marks a structural change to US prescription-drug pricing for seniors.
This fact’s slice of Factrail’s verified causal web — the people, facts, drivers and welfare indicators it connects to. Select any node to trace a path.
Loading network…
Lower negotiated prices on widely used medicines directly reduce out-of-pocket health costs for older households, easing cost-of-living pressure for that group.